Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (450)	11/11/2002 12:14:50 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1022

bizarre terminology. this is where the science of human MAbs first started out. in a collaboration with Genetic Systems (subsequently Oncogen, subsequently Bristol Myers-Squibb Research Institute), we at Bayer (Cutter) assembled a cocktail of human MAbs (derived from EBV transformants) directed to the various serotypes of Pseudomonas aeruginosa LPS. it's not as straight forward as it may seem. your excipients need to prevent MAb-MAb interactions, and quality control needs to be done for each MAb separately before it's repeated for the cocktail.